FDA Accepts New Drug Application (NDA) for Rabeprazole Sodium Extended-Release 50 mg for Patients with …

Published June 7, 2010

FDA Accepts New Drug Application (NDA) for Rabeprazole Sodium Extended-Release 50 mg for Patients with …
WOODCLIFF LAKE, N.J.—-Eisai Inc. , a U.S. subsidiary of Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted Eisai’s New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease , and for the treatment of symptomatic GERD.